- IPO date: November 8, 2021
- Denomination: MaaT Pharma
- ISIN code/ticker: FR0012634822 / MAAT
- ICB classification: 20103010 – Biotechnology
- Listing market: Euronext Paris regulated market
- Eligible for the PEA and PEA-PME schemes and for the 150-0 B ter scheme of the CGI
- Analysts covering the share:
- KBC Securities: Thomas Vranken & Jacob Mekhael
- Kempen: Suzanne van Voorthuizen & Luísa Morgado
- Kepler Cheuvreux: Christophe Dombu
- Portzamparc Groupe BNP Paribas: Mohamed Kaabouni
Building a leading microbiome company in oncology
We are the first company developing microbiome-based drugs listed on the regulated market of Euronext Paris.
Stock information
Board of Directors
Based in the U.S., Karim Dabbagh, president and CEO of Second Genome Inc., renowned for his innovative work in microbiome science and former executive at Pfizer and Roche, brings extensive experience in pharmaceutical development.
PhD in Biochemistry from University College, London
BSc (Hons) in Biotechnology from Imperial College, London
Jean-Marie Lefèvre has held senior manage-ment positions in large companies such as LVMH and Bongrain before joining Biocodex where he was Chairman and CEO until the end of 2020 and of which he is currently Chairman. During his ten-ure as CEO at Biocodex, he initiated the creation of numerous subsidiaries, and greatly diversified the product portfolio of the Biocodex Group. At the same time, he wanted his Group to invest in and support the development of healthcare start-ups, including MaaT Pharma.
Engineering degree Ecole Centrale Paris, MBA from Insead
She was formerly HR Director EMEA at Google and HR Director France at AOL.
Chief Corporate and People Operations Officer
Engineer, MBA,
CFO
Graduated from HEC Paris and Bocconi University in Milan
PharmD, PhD
Engineering degree from Ecole Centrale Paris
Doctorate in immuno-analysis and innovation in clinical biology - Sanofi Diagnostics Pasteur / CNRS
Master's degree in Business Administration from IAE Poitiers
Artificial Intelligence in Health University Diploma at Université Paris Cité
Events & Presentations
2024
- February 2024 – Corporate Presentation
2023
- January 2024 – Corporate Presentation
- December 18th, 2023- KOL discussion on data presented at ASH 2023 Annual Meeting
2022
- December 12, 2022 – Investor webcast ASH congress
- June 07, 2022 – R&D Day
- January 10-13, 2022 – H.C Wainwright Bioconnect 2022 Conference replay
- 2022 – Operation Note
2021
December, 13 2021 – Investors Webcast – Corporate Update
2021 – Financial Annual Report – Only in French
Regulated information
2023
- 2023 Half-Year Financial Report – Only in French
- 2022 Universal Registration Document – Only in French
2022
- 2022 – Half Year Financial Report – Only in French
- 2022- Universal Registration Document – Only in French
- May 31, 2022 – Information on the compensation of corporate officers
- February 09, 2022 – Number of shares and voting rights – Only in French
- January 26, 2022 – Number of voting rights
- January 03, 2022 – Number of shares and voting rights – Only in French
2021
2021 – Registration Document
General Meetings
2023
23/06/19 - Annual Combined General Meeting - Documents
Preparatory documents
- Notice of meeting BALO announcement – French only
- Convening Notice AGM
- Information on the total number of voting rights and shares comprising the share capital on May 12, 2023
- AGM voting form – French only
- Request for additional documents and information
- Report of the Board of Directors to GM2023
- Text of resolutions OAEGM 2023 EN
- MaaT Pharma AGM_Renewals of terms of office BoD members
- Appointment Proposal for an Independent Director: Karim Dabbagh, PhD
- Appointment Proposal for an Independent Director: Nadia Kamal
- Statutory Auditors report – AGM 190623 – Compensations – French only
- Statutory Auditors report – AGM 190623 – Financial results – French only
- Statutory Auditors’ special report – AGM 190623 – regulated agreements – French only
2022
05/31/22 - Annual Combined General Meeting documents
- Minutes of the annual combined general meeting – Only in French
- April 25, 2022 – Number of voting rights
- Notice of meeting BALO announcement – Only in French
03/03/22 - Combined General Meeting - (ordinary & extraordinary)
- Minutes of the combined general meeting (ordinary and extraordinary) – Only in French
- Auditors’ reports on the share capital decrease – Only in French
- Ordinary and extraordinary Shareholders’ General Meeting – Press Release
- Notice of meeting to the ordinary and extraordinary General Meeting – Only in French
Provisional financial calendar*
2024*
- March 28, 2024: Annual Results
- May 14, 2024: Publication of revenues for Q1 2024
- May 28, 2024: Annual General Shareholders Meeting
- September 19, 2024: Publication of half year financial results H1
- November 5, 2024: Publication of revenues for Q3 2024
*Indicative calendar could be subject to change.
Investor contact
Guilhaume Debroas, PhD.
Head of Investor Relations
Email: invest@maat-pharma.com
Phone: +33 (0) 6 16 48 92 50
MaaT Pharma
70 avenue Tony Garnier
69007 Lyon